Literature DB >> 19505274

Diuretics: still essential drugs for the management of hypertension.

Flávio Danni Fuchs1.   

Abstract

According to most current international guidelines for hypertension, diuretics are indicated for elderly and black patients, unless they have any of a long list of other preferential indications. These recommendations are mostly based on the results of corporate-sponsored and biased trials, which have unsuccessfully tried to demonstrate the existence of pleiotropic effects of newer agents. Metaregression analyses have shown that the benefits of treatments are directly proportional to the difference in blood pressure between trial arms. New analyses of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack (ALLHAT) trial demonstrated the superiority of chlorthalidone over other agents in the prevention of end-stage renal disease in diabetics and of cardiovascular events in newer cases of diabetes. Despite this evidence, patients continue to withdraw from effective therapies in recent trials. The use of diuretics has also been challenged by the results of the Avoiding Cardiovascular Events in Combination Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial, which employed hydrochlorothiazide, a diuretic with lower potency and duration of action than chlorthalidone. Diuretics are still essential drugs for hypertension management, but diuretics with higher potency and duration of action, such as chlorthalidone, should be preferred.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19505274     DOI: 10.1586/erc.09.32

Source DB:  PubMed          Journal:  Expert Rev Cardiovasc Ther        ISSN: 1477-9072


  4 in total

1.  A comparison between diuretics and angiotensin-receptor blocker agents in patients with stage I hypertension (PREVER-treatment trial): study protocol for a randomized double-blind controlled trial.

Authors:  Flávio D Fuchs; Sandra C Fuchs; Leila B Moreira; Miguel Gus; Antônio C Nóbrega; Carlos E Poli-de-Figueiredo; Décio Mion; Luiz Bortolotto; Fernanda Consolim-Colombo; Fernando Nobre; Eduardo Barbosa Coelho; José F Vilela-Martin; Heitor Moreno; Evandro José Cesarino; Roberto Franco; Andréa Araujo Brandão; Marcos R de Sousa; Antônio Luiz Pinho Ribeiro; Paulo Cesar Jardim; Abrahão Afiune Neto; Luiz César N Scala; Marco Mota; Hilton Chaves; João Guilherme Alves; Dario C Sobral Filho; Ricardo Pereira e Silva; José A Figueiredo Neto; Maria Cláudia Irigoyen; Iran Castro; André Avelino Steffens; Rosane Schlatter; Renato Bandeira de Mello; Francisca Mosele; Flávia Ghizzoni; Otávio Berwanger
Journal:  Trials       Date:  2011-02-24       Impact factor: 2.279

2.  Night blood pressure responses to atenolol and hydrochlorothiazide in black and white patients with essential hypertension.

Authors:  Arlene B Chapman; George Cotsonis; Vishal Parekh; Gary L Schwartz; Yan Gong; Kent R Bailey; Stephen T Turner; John G Gums; Amber L Beitelshees; Rhonda Cooper-DeHoff; Eric Boerwinkle; Julie A Johnson
Journal:  Am J Hypertens       Date:  2013-07-25       Impact factor: 2.689

3.  Prevention of hypertension in patients with pre-hypertension: protocol for the PREVER-prevention trial.

Authors:  Flávio D Fuchs; Sandra C Fuchs; Leila B Moreira; Miguel Gus; Antônio C Nóbrega; Carlos E Poli-de-Figueiredo; Décio Mion; Luiz Bortoloto; Fernanda Consolim-Colombo; Fernando Nobre; Eduardo Barbosa Coelho; José F Vilela-Martin; Heitor Moreno; Evandro José Cesarino; Roberto Franco; Andréa Araujo Brandão; Marcos R de Sousa; Antônio Luiz Pinho Ribeiro; Paulo Cesar Jardim; Abrahão Afiune Neto; Luiz César N Scala; Marco Mota; Hilton Chaves; João Guilherme Alves; Dario C Sobral Filho; Ricardo Pereira e Silva; José A Figueiredo Neto; Maria Cláudia Irigoyen; Iran Castro; André Avelino Steffens; Rosane Schlatter; Renato Bandeira de Mello; Francisca Mosele; Flávia Ghizzoni; Otávio Berwanger
Journal:  Trials       Date:  2011-03-05       Impact factor: 2.279

4.  Effectiveness of Chlorthalidone Plus Amiloride for the Prevention of Hypertension: The PREVER-Prevention Randomized Clinical Trial.

Authors:  Sandra Costa Fuchs; Carlos E Poli-de-Figueiredo; José A Figueiredo Neto; Luiz César N Scala; Paul K Whelton; Francisca Mosele; Renato Bandeira de Mello; José F Vilela-Martin; Leila B Moreira; Hilton Chaves; Marco Mota Gomes; Marcos R de Sousa; Ricardo Pereira E Silva; Iran Castro; Evandro José Cesarino; Paulo Cesar Jardim; João Guilherme Alves; André Avelino Steffens; Andréa Araujo Brandão; Fernanda M Consolim-Colombo; Paulo Ricardo de Alencastro; Abrahão Afiune Neto; Antônio C Nóbrega; Roberto Silva Franco; Dario C Sobral Filho; Alexandro Bordignon; Fernando Nobre; Rosane Schlatter; Miguel Gus; Felipe C Fuchs; Otávio Berwanger; Flávio D Fuchs
Journal:  J Am Heart Assoc       Date:  2016-12-13       Impact factor: 5.501

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.